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OBJECTIVES The study aimed to assess the hemodynamic and neuroendocrine effects of candoxatril and
frusemide compared with placebo in patients with mild chronic heart failure.
BACKGROUND Candoxatril is an atriopeptidase inhibitor. It increases circulating levels of atrial natriuretic
peptide leading to natriuresis and diuresis, which alleviate the symptoms of a failing heart.
METHODS This was a multicenter, randomized, double-blind study. Forty-seven patients with mild
stable chronic heart failure received candoxatril 400 mg/day, frusemide 40 mg/day or placebo
for up to six weeks. Cardiac indices were determined at rest and during exercise, and blood
samples were taken for laboratory analysis. Assessments were performed at baseline (day 0)
and after six weeks (day 42).
RESULTS In comparison with placebo, both drugs significantly reduced mean pulmonary capillary
wedge pressure following the first dose administration. Only candoxatril significantly reduced
pulmonary capillary wedge pressure during exercise on day 0, while both drugs significantly
reduced this parameter on day 42. Changes in the remaining hemodynamic parameters were
comparable for both drugs relative to placebo. Frusemide significantly increased mean plasma
renin activity (days 0 and 42), and the mean aldosterone concentration (day 42) in comparison
with placebo, whereas candoxatril caused no significant changes in any of the hormonal
parameters assessed.
CONCLUSIONS These results show that candoxatril, 400 mg/day, has a similar hemodynamic profile to
frusemide, 40 mg/day, but it does not induce adverse neuroendocrine effects. Candoxatril
therefore appears to offer a clinically significant advantage over frusemide, providing an
alternative therapeutic approach to the treatment of patients with mild stable chronic heart
failure. (J Am Coll Cardiol 1999;34:1794–801) © 1999 by the American College of
Cardiology
Despite the advances that have been made in the under-
standing and treatment of heart failure over the past decade,
the incidence of the disease continues to rise (1). Once
diagnosed, patients have a prognosis worse than for many
cancer patients, with a five-year mortality rate of about 50%
(1). With improved survival among acute myocardial infarc-
tion patients, and an aging population, more people are
progressing to a failing heart, and this significant public
health problem will certainly continue to grow (1).
Symptoms of a failing heart are alleviated by measures
such as rest, restriction of sodium and fluid to unload the
decompensating heart, therapy with inotropic agents to
improve the mechanical performance of the heart, and with
agents to counteract the activated sympathetic nervous
system and the renin-angiotensin-aldosterone system (2).
These symptoms, however, still limit the everyday activities
of most heart failure patients (1), highlighting the need for
new therapies in this setting.
Heart failure therapy continues to improve, and
angiotensin-converting enzyme (ACE) inhibitors are the
most important recent development (1,3). These agents
reduce the harmful long-term consequences of neurohor-
monal/autocrine–paracrine effects, and they slow the pro-
gression of left ventricular (LV) dysfunction or ventricular
remodeling (4). Other therapies include treatment with
beta-blockers and diuretics, while concomitant vasodilator
therapy with some of the newer calcium channel blockers is
currently under investigation (3). These therapies aim to
provide symptomatic control, leading to an increase in
exercise tolerance.
Atriopeptidase inhibitors are a new class of agent pro-
ducing natriuresis and diuresis. Studies are currently inves-
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tigating whether these agents have a role in the pathophys-
iology and therapy of various diseases, such as congestive
heart failure and certain forms of hypertension (5). Atrio-
peptidase inhibitors have been shown to alleviate symptoms
of a failing heart (5,6) and to increase exercise tolerance.
Candoxatril is an orally active prodrug of candoxatrilat, an
atriopeptidase inhibitor that has been shown to lower blood
pressure in animals with established hypertension.
Current studies are investigating the dose-response rela-
tionship, duration of action, hemodynamic effects and safety
of oral candoxatril for the treatment of patients with
hypertension and heart failure. In early placebo-controlled
clinical studies, candoxatril has been shown to confer
beneficial acute hemodynamic effects in patients with con-
gestive heart failure and to be well tolerated (7,8). Further-
more, its efficacy is maintained with chronic therapy (7,9).
These results indicate that candoxatril has therapeutic po-
tential in chronic congestive heart failure (7,8).
The diuretic frusemide has beneficial effects on the
hemodynamic profile, but it has an adverse effect on levels of
renin and aldosterone. Initial placebo-controlled trials in
patients with LV dysfunction have shown that candoxatril
has a similar hemodynamic profile to frusemide but no
adverse neuroendocrine effects in an acute setting (10).
This six-week study compared the hemodynamic and
neuroendocrine effects of candoxatril 400 mg/day and
frusemide 40 mg/day with placebo in patients with mild
stable chronic heart failure to evaluate whether longer-term
administration of candoxatril maintained the beneficial
effects shown earlier in acute investigations.
METHODS
Selection of patients. Patients aged 18 to 75 years with
stable mild chronic heart failure and an ejection fraction
,50% were eligible for inclusion into this multicenter,
double-blind, double-dummy, parallel-group comparison.
Stable mild heart failure was defined as New York Heart
Association (NYHA) class I or II heart failure that had been
in the same functional class for the previous two weeks.
The patient population comprised those currently on no
treatment, but requiring monotherapy with diuretics, or
those already on diuretic treatment who could, in the
opinion of the investigator, be safely discontinued. After a
two-week placebo run in, patients with a pulmonary capil-
lary wedge pressure (PCWP) of $25 mm Hg (exercise) and
,21 mm Hg (rest) were randomized to receive either
candoxatril 200 mg twice daily, frusemide 40 mg once daily,
or placebo for six weeks.
Exclusion criteria covered women of childbearing poten-
tial, patients who had suffered a myocardial infarction,
cerebrovascular accident or those who had undergone car-
diac surgery, in the preceding three months. Also excluded
were patients with any other clinically significant disease
likely to affect the degree of heart failure or the hemody-
namic response to exercise, patients who required continued
therapy with other cardiovascular drugs, or patients whose
weight gain was $2.5 kg in the initial two-week placebo
run-in period.
Forty-three patients were receiving concomitant medica-
tion (mostly anti-inflammatory drugs) on entry into the
study. All patients gave their written informed consent
before entry. Experimental procedures were reviewed and
approved by the appropriate independent Ethics Commit-
tees, and conducted in compliance with the revised decla-
ration of Helsinki.
Study protocol. Patients who met the selection criteria
underwent a screening visit during which demographic data,
medical history, intercurrent illnesses, allergies and concom-
itant therapy were documented. In addition, patients un-
derwent a full physical assessment that included measure-
ment of blood pressure, heart rate, body weight and height.
Blood and urine samples were obtained for routine labora-
tory investigation and a 12-lead electrocardiogram (ECG)
was performed. Left ventricular ejection fraction had been
measured within the preceding eight weeks.
On the first (day 0) and last (day 42) days of treatment,
patients underwent a cardiovascular examination that in-
cluded measurement of blood pressure, heart rate and
assessment of NYHA class. A 12-lead resting ECG, blood
samples for hematological and biochemical testing, and a
urine sample for analysis were obtained. Patients were
instructed not to take their morning medication before
attendance, and invasive hemodynamic measurements were
taken before and after double-blind medication was given.
The primary efficacy parameters were PCWP and cardiac
index (CI) at rest and during exercise on days 0 and 42 and
discontinuation due to worsening heart failure. Systemic
vascular resistance and pulmonary vascular resistance at
rest and exercise together with NYHA classification and
circulating hormone levels were also determined on days
0 and 42.
Hemodynamic analysis. Hemodynamic measurements
were taken on day 0 and day 42. Patients underwent a
supine bicycle exercise test to determine the load required to
produce fatigue, shortness of breath, or for the heart rate to
exceed 150 beats/min. Patients then underwent cardiac
catheterization and measurement of PCWP at rest. Cath-
eterization was performed with a four-channel thermodilu-
tion catheter (Swan-Ganz) inserted through an antecubital
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANP 5 atrial natriuretic peptide
CI 5 cardiac index
ECG 5 electrocardiogram
LV 5 left ventricular
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fossa vein. The catheter was positioned in the right atrium,
right ventricle and pulmonary artery; a brachial or radial
artery cannula was also inserted. Systemic blood pressure
was continuously monitored using a transducer attached to
the arterial line, and the heart rate was simultaneously taken
from the ECG.
Hemodynamic measurements included mean right artrial
pressure, systolic, diastolic and mean pulmonary artery
pressure, PCWP, mean arterial pressure and cardiac output.
These were made in duplicate in the supine position, and
cardiac output was determined by thermodilution. From
these parameters, the CI, systemic vascular resistance and
pulmonary vascular resistance were calculated.
Patients underwent a second exercise test and hemody-
namic measurements were made at 1-min intervals during
exercise. Resting hemodynamic measurements were then
taken until four consecutive measurements of PCWP,
cardiac output and mean arterial pressure showed a stable
baseline. Resting hemodynamic measurements were made
at 1, 2, 3, 4 and 6 h following administration of medication.
At 2 and 6 h after dose administration, patients underwent
supine bicycle exercise tests using the same load and
protocol as in the first exercise test.
Hormonal analysis. Distributions of the hormonal param-
eters in the three treatment groups were assessed for plasma
renin activity and norepinephrine, aldosterone and angio-
tensin II concentrations. Blood samples were taken on days
0 and 42 immediately after exercise before the dose and at 2
and 6 h after administration.
Adverse event analysis. All adverse events, concomitant
illnesses and therapeutic interventions were recorded by the
investigator at each visit and assessed for causality. Serious
adverse events were categorized as fatal, life-threatening,
permanently disabling, requiring in-patient hospitalization,
congenital anomaly, cancer or the result of an overdose,
significant enough to merit immediate reporting. Abnormal
values in laboratory tests of hematology, clinical chemistry,
urinalysis and hepatitis battery were followed up with
appropriate medical management if necessary.
On completion of these measurements, patients were
discharged unless they had developed complications, stand-
ing systolic blood pressure was #85 mm Hg, or hemostasis
was not established.
Statistical analysis. Hemodynamic variables were analyzed
using one way analysis of variance (ANOVA) with treat-
ment as the grouping factor. The baseline term was included
in each model as a covariate as was the interaction between
the baseline term and the treatment. Least-square means,
adjusted for the baseline terms, were used in the compari-
sons. The sample size was sufficient to detect a difference of
4 mm Hg in PCWP between treatments using a signifi-
cance level of a 5 0.05 and with a power of 80%. This
assumed a between-subject standard deviation of changes
from baseline of 3.8 mm Hg. No direct statistical compar-
isons were made between the two active treatment groups.
The hormonal data were log-transformed to improve the
normality of these data and analyzed using the same model
as for the hemodynamic data. Worsening of heart failure
was compared between the active-treatment and placebo
groups using a continuity adjusted chi-square test. Pairwise
comparisons of each active treatment with placebo were
made using a pooled estimate of error from the ANOVA
model, and 95% confidence intervals for treatment differ-
ences were calculated.
All statistical analyses were performed using SAS (version
6.09), and all tests were two-tailed at the 5% significance level.
RESULTS
Of the 72 patients screened, 47 were eligible for inclusion in
the study. Of these, 15 patients were randomized to receive
candoxatril, 16 patients were randomized to receive
frusemide, and 16 patients were randomized to receive
Table 1. Baseline Characteristics of the Study Population
Candoxatril
(n 5 15)
Frusemide
(n 5 16)
Placebo
(n 5 16)
Mean age (yrs) 63 (43–75) 61 (45–70) 64 (52–73)
Gender (men/women) 15/0 14/2 15/1
Ischemic heart disease 7 8 7
Mean duration of heart failure (yrs) 3 (0–6) 4 (0–8) 4 (0–10)
Left ventricular ejection fraction
% (mean 6 SD) 43.1 6 6.3 34.6 6 9.7 39.4 6 6.0
NYHA class
Grade I 10 10 7
Grade II 5 6 9
Mean body weight (kg) 82 (68–93) 80 (52–101) 76 (63–96)
Concomitant therapy
Aspirin 9 11 11
Oral anticoagulant 1 2 1
Lipid-lowering drugs 1 3 1
Range quoted in parentheses. There was no significant difference between the groups.
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placebo. A summary of the baseline characteristics of the
patient population is shown in Table 1. All patients in the
candoxatril and frusemide groups, and 14 of the 16 patients
in the placebo group completed the study. One patient
discontinued owing to tiredness, the other because of an
adverse event considered to be related to a concurrent
illness.
Hemodynamics. The primary variables analyzed at rest
were the maximum change (increase or decrease) from the
predose baseline during the 6-h postdose period (defined as
peak effect), and the time to achieve this, on both day 0 and
day 42. In addition, the differences between the predose
baselines on day 42 and day 0 were analyzed. After exercise,
the 6-h value was used in the same comparisons and
analyses as the “peak effect” at rest.
Pulmonary capillary wedge pressure. REST. On day 0, the
peak fall in the mean PCWP from baseline (minimum at
3.7 h postdose) relative to placebo was statistically signifi-
cant for both candoxatril (22.5 6 0.91 mm Hg, p 5 0.009)
and frusemide (22.4 6 0.91 mm Hg, p 5 0.012). The
PCWP rose at 6 h postdose in both groups. The adjusted
mean time to peak effect was statistically significantly higher
for candoxatril only (3.7 h 6 0.36), compared with placebo
(2.4 h 6 0.35, p 5 0.017). On day 42, the adjusted mean
change from baseline to peak effect between 0 and 6 h
postdose reached statistical significance compared with
placebo in the frusemide group only (22.4 6 1.09 mm Hg,
p 5 0.037) (Table 2).
EXERCISE. On day 0, the fall in mean PCWP from predose
baseline to 6 h postdose relative to placebo was statistically
significantly greater for candoxatril (210.6 6 2.69 mm Hg,
p , 0.001) but not for frusemide (24.1 mm Hg 6 2.67,
p 5 0.13). On day 42, the fall in mean PCWP relative to
placebo reached statistical significance, and was greater for
both treatment groups (candoxatril: 25.2 6 2.29 mm Hg,
p 5 0.028; frusemide: 26.1 6 2.29 mm Hg, p 5 0.011
[Table 2]). There was no statistically significant difference
in the mean change in PCWP relative to placebo between
the day 0 and day 42 results for either group.
Cardiac index. REST. The reduction in the mean CI on day
0 was statistically significantly greater in both active treat-
ment groups compared with placebo (candoxatril: 20.32 6
0.107 liter/min21/m2, p 5 0.004; frusemide: 20.29 6
Table 2. Pulmonary Capillary Wedge Pressure, mm Hg, Days 0 and 42 (Mean 6 SE)
Day
Treatment
Group
Baseline
(predose)
Change from
Baseline
Difference in Change
from Baseline to Peak
Effect Compared with
Placebo (significance)
At Peak Effect (0–6 h)—Resting
0
Candoxatril
(n 5 15)
9.3 6 1.0 25.6 6 0.6 22.5 6 0.9 (p 5 0.009)
Frusemide
(n 5 16)
11.2 6 1.4 25.5 6 0.6 22.4 6 0.9 (p 5 0.012)
Placebo
(n 5 16)
8.9 6 1.0 23.1 6 0.6 —
42
Candoxatril
(n 5 15)
8.6 6 1.0 24.0 6 0.8 21.4 6 1.1 (p 5 0.22)
Frusemide
(n 5 16)
10.7 6 1.6 25.0 6 0.7 22.4 6 1.1 (p 5 0.037)
Placebo
(n 5 14)
8.9 6 1.5 22.7 6 0.8 —
At 6 h Postdose—After 6-min Exercise
0
Candoxatril
(n 5 15)
32.0 6 1.8 214.4 6 1.9 210.6 6 2.7 (p , 0.001)
Frusemide
(n 5 15)
34.5 6 2.1 27.9 6 1.9 24.1 6 2.7 (p 5 0.13)
Placebo
(n 5 15)
33.5 6 1.9 23.8 6 1.9 —
42
Candoxatril
(n 5 15)
28.7 6 2.0 25.3 6 1.6 25.2 6 2.3 (p 5 0.028)
Frusemide
(n 5 16)
34.6 6 2.3 26.2 6 1.5 26.1 6 2.3 (p 5 0.011)
Placebo
(n 5 13)
32.3 6 2.6 20.1 6 1.7 —
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0.105 liter/min21/m2, p 5 0.008). The mean time to peak
effect was not statistically significant compared with placebo
for candoxatril or frusemide on either day 0 or day 42.
EXERCISE. No statistically significant different changes oc-
curred in CI relative to placebo in either the candoxatril or
frusemide groups on either day 0 or day 42.
Systemic vascular resistance. REST. On day 0, the mean
change from baseline to peak effect for systemic vascular
resistance relative to placebo between 0 and 6 h postdose
was not statistically significant for candoxatril (127.86 6
73.635 dynes/s/cm25, p 5 0.09) but increased and reached
statistical significance for frusemide (174.76 6 72.123
dynes/s/cm25, p 5 0.02). The mean time to peak effect
relative to placebo was not statistically significantly different
for either drug on day 0 or day 42.
EXERCISE. There were no statistically significant changes in
systemic vascular resistance relative to placebo in the active
treatment groups on either day 0 or day 42.
Pulmonary vascular resistance. The mean change from
baseline, or mean time to peak effect relative to placebo, was
not statistically significant for either candoxatril or
frusemide after rest or exercise on days 0 or 42 (Table 3).
Neuroendocrine effects. Candoxatril induced no statisti-
cally significant change in plasma renin activity, aldosterone
angiotensin II or norepinephrine on day 0. On day 42, the
mean difference (log transformed) between the candoxatril
and placebo groups reached statistical significance for the
plasma renin activity parameter at 2 h postdose (p 5 0.011),
but this difference was no longer statistically significant at
6 h postdose. Frusemide caused a statistically significant
increase in the plasma renin activity on days 0 and 42 (Fig.
1). The mean difference between plasma renin activity (log
transformed) at baseline and 6 h postdose relative to placebo
was 10.436 6 0.1226 mg/liter/h, p 5 0.001, on day 0, and
10.305 6 0.1247 mg/liter/h, p 5 0.019, on day 42. Frusemide
also caused a statistically significant change in the mean
aldosterone concentration relative to placebo on day 42
(10.281 6 0.0958 nmol/liter, p 5 0.006), but not in any of the
other parameters (Fig. 2, Table 4).
Cardiovascular examination. Most patients did not expe-
rience any symptoms of paroxysmal nocturnal dyspnea,
Table 3. Pulmonary Vascular Resistance, dynes/s/cm25, Days 0 and 42 (Mean 6 SE)
Day
Treatment
Group
Baseline
(predose)
Change from
Baseline
Difference in Change
from Baseline to Peak
Effect Compared with
Placebo (significance)
At Peak Effect (0–6 h)—resting
0
Candoxatril
(n 5 15)
124 6 15.41 225 6 13.73 3 6 19.42 (p 5 0.86)
Frusemide
(n 5 15)
116 6 12.66 29 6 13.77 19 6 19.51 (p 5 0.35)
Placebo
(n 5 15)
129 6 12.67 228 6 13.75 —
42
Candoxatril
(n 5 15)
115 6 16.69 234 6 10.06 213 6 14.76 (p 5 0.40)
Frusemide
(n 5 16)
117 6 23.51 218 6 9.74 4 6 14.55 (p 5 0.80)
Placebo
(n 5 13)
116 6 13.02 221 6 10.81 —
At 6 h Postdose—After 6-min Exercise
0
Candoxatril
(n 5 6)
80 6 17.13 14 6 21.97 233 6 40.21 (p 5 0.43)
Frusemide
(n 5 7)
72 6 31.03 24 6 20.82 251 6 40.73 (p 5 0.24)
Placebo
(n 5 3)
129 6 37.10 47 6 33.37 —
42
Candoxatril
(n 5 5)
85 6 27.95 16 6 28.11 7 6 39.55 (p 5 0.86)
Frusemide
(n 5 7)
103 6 17.38 5 6 23.62 24 6 36.39 (p 5 0.91)
Placebo
(n 5 5)
102 6 26.69 9 6 27.73 —
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orthopnea or ankle/pedal edema at screening or on days 0
and 42. There was a decrease in dyspnea (after climbing one
flight of stairs) on days 0 and 42 in all treatment groups
compared with the screening visit.
Worsening of heart failure. One patient in the candoxatril
group and five in the frusemide group experienced a worsen-
ing of heart failure. The incidence was not statistically
significantly different compared with placebo (two patients).
Figure 1. Plasma renin activity (mg/liter/h). Geometric mean over time on day 0 and day 42.
Figure 2. Aldosterone concentration (nmol/liter). Geometric mean over time on day 0 and day 42.
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Most patients showed either improvements or no change in
NYHA classification at day 42 compared with day 0.
Adverse events. In the candoxatril group, 6 of the 15
patients had treatment-emergent adverse events compared
with 4 of 16 patients taking frusemide and 7 of 16 receiving
placebo. The most common adverse events reported during
candoxatril treatment were symptoms of the central and
peripheral nervous system including dizziness (one), head-
ache (one) and vertigo (one). The adverse events of three
candoxatril-treated patients, two frusemide-treated patients
and one placebo-treated patient were considered by the
investigator to be treatment related, and were mild to
moderate in severity. One patient had a serious adverse
event during placebo treatment (bronchitis with congestion
of seven days’ duration and moderate severity).
Other safety parameters. All laboratory test results outside
normal range were considered by the investigator to be
unrelated to treatment. No patient experienced a clinically
significant change in ECG compared with baseline ECG.
In the candoxatril group a reduction in body weight from
baseline to day 42 was statistically significant compared with
placebo (difference: 20.92 kg, p 5 0.036). There was no
statistically significant difference in body weight recorded
over the study period in the frusemide group compared to
placebo.
DISCUSSION
We have demonstrated that candoxatril (200 mg twice
daily) is associated with a beneficial hemodynamic effect
both at rest and during exercise. The effects were compara-
ble to those observed following frusemide (40 mg once
daily) administration. We were further able to demonstrate
that the beneficial hemodynamic effects associated with
candoxatril are maintained during long-term therapy in the
absence of harmful, activating effects on neuroendocrine
function. Both candoxatril and frusemide significantly im-
proved hemodynamic parameters compared with placebo,
and although direct statistical comparisons were not made,
the hemodynamic profiles of both drugs were comparable.
Previous studies. Elsner et al. (9) conducted a randomized,
placebo-controlled, double-blind trial on 12 patients with
stable functional (class II and III) congestive heart failure.
On day 10, the acute effects of candoxatril (determined by
direct measurement of plasma atrial natriuretic peptide
(ANP) levels, aldosterone levels and PCWP) detected on
day 1 were still apparent, indicating a long-lasting effective-
ness. The results of the present study extend this observa-
tion and show that, although the hemodynamic parameters
measured were attenuated after 42 days, there was still a
statistically significant reduction compared with placebo in
PCWP after exercise following candoxatril treatment.
Potential explanations. The fall in CI compared to pla-
cebo in both groups of patients at rest was not seen inTa
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patients after exercise, probably due to the low LV filling
pressure in the resting state. However, it seems unlikely that
the reduction in CI at rest should have any adverse effect on
cardiac function.
The mechanisms for the fall in LV filling pressure in the
candoxatril group might be an increase in plasma ANP as
has been observed previously (9). In our study, plasma ANP
was not measured, but the acute hemodynamic effect of
candoxatril in this study is similar to earlier findings,
indicating that the biological consequence of candoxatril
treatment is caused by elevated ANP concentration. In
addition, the effect of candoxatril on hemodynamic param-
eters was maintained after long-term use during exercise.
Neuroendocrine effects. Unlike frusemide, the beneficial
hemodynamic effects of candoxatril are observed in the
absence of clinically relevant effects on the renin-
angiotensin-aldosterone system in patients with mild
chronic heart failure. Although activation of this hormonal
system may be beneficial in the short term, it results in
long-term and progressive dysfunction of the heart (4).
Candoxatril produced no statistically significant increase in
any hormonal parameter. This is likely to be particularly
beneficial as activation of neurohormones is thought to have
a negative impact on the prognosis of patients with conges-
tive heart failure (11).
High plasma renin levels are associated with an increased
risk of myocardial infarction in hypertensive patients (12).
Furthermore, increased levels of both renin and aldosterone
are thought to negatively affect the prognosis of patients
with congestive heart failure (13). In the SOLVD (14,15)
prevention trial, only patients already on treatment with
diuretics had elevated plasma renin levels. Candoxatril, in
contrast to frusemide, does not have any adverse neurohor-
monal effects and might, therefore, be more useful than
diuretics in the long-term treatment of congestive heart
failure.
Clinical effects and safety. In congestive heart failure,
changes in body weight might reflect variations in the water
and sodium balance. Diuresis was not measured in this
study, but all patients were told to maintain a constant diet
and fluid intake, and not to change their normal levels of
physical activity. Therefore, the slight but significant reduc-
tion in body weight observed in the candoxatril group is
suggestive of a beneficial diuretic effect.
Only one patient treated with candoxatril experienced a
worsening of heart failure compared with five patients in the
group treated with frusemide. However, this frequency was
not statistically significantly different from that observed in
the placebo-treated group (two patients) for either drug.
Both the frequency and the severity of other adverse events
were minimal and similar in both the candoxatril and
frusemide treatment groups compared with placebo.
Clinical implications. Taken together, the results of this
study support the current evidence that candoxatril offers a
new and effective therapeutic approach in the treatment of
patients with mild heart failure (9,10) without the adverse
activation of the renin-angiotensin-aldosterone neuroendo-
crine system. The reductions in LV filling pressure mea-
sured as PCWP might also have clinical implications by
relieving congestion and dyspnea during physical effort.
These beneficial effects may improve the well-being of
patients during everyday activities. However, to show the
real potential of this drug, further long-term studies in
combination with ACE inhibitors are needed.
Reprint requests and correspondence: Dr. Arne S. Westheim,
Department of Cardiology, Ulleva´l Hospital, 0407 Oslo, Norway.
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